These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21777819

  • 41. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 42. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 43. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 44. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
    Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB.
    Lancet Neurol; 2007 May 30; 6(5):431-41. PubMed ID: 17434098
    [Abstract] [Full Text] [Related]

  • 45. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 30; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 46. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    Jeantin L, Shor N, Pallix-Guyot M, Roos-Weil D, Bellanger A, Le Garff-Tavernier M, Papeix C, Weiss N, Pourcher V.
    J Neurol; 2024 Feb 30; 271(2):729-732. PubMed ID: 37910249
    [No Abstract] [Full Text] [Related]

  • 47. Safety of monoclonal antibodies for the treatment of multiple sclerosis.
    McGinley MP, Moss BP, Cohen JA.
    Expert Opin Drug Saf; 2017 Jan 30; 16(1):89-100. PubMed ID: 27756172
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan 30; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC.
    Mult Scler; 2011 Feb 30; 17(2):151-6. PubMed ID: 21078695
    [Abstract] [Full Text] [Related]

  • 54. Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
    Stüve O, Wiendl H.
    Neurology; 2009 Oct 27; 73(17):1346-7. PubMed ID: 19776376
    [No Abstract] [Full Text] [Related]

  • 55. Patients at risk.
    Drazen JM.
    N Engl J Med; 2005 Jul 28; 353(4):417. PubMed ID: 15947081
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
    Langer-Gould A, Steinman L.
    Curr Neurol Neurosci Rep; 2006 May 28; 6(3):253-8. PubMed ID: 16635435
    [Abstract] [Full Text] [Related]

  • 58. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.
    Neurology; 2012 Nov 20; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract] [Full Text] [Related]

  • 59. The return of natalizumab: weighing benefit against risk.
    Goodin D.
    Lancet Neurol; 2006 May 20; 5(5):375-7. PubMed ID: 16632301
    [No Abstract] [Full Text] [Related]

  • 60. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F, Perini P, Calabrese M, Rinaldi L, Gallo P.
    Mult Scler; 2009 Nov 20; 15(11):1359-62. PubMed ID: 19812116
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.